[at Seeking Alpha] – Pfizer ( PFE ) has high hopes for its experimental breast cancer drug palbociclib (PD-0332991), an oral inhibitor of CDK (cyclin-dependent kinases) 4 and 6. The therapy generated excitement . . . → Read More: Pfizer Vs. Novartis: A New Era In Breast Cancer Treatment – Pfizer Inc. (NYSE:PFE) Similar posts: Company Update: Johnson & Johnson (NYSE:JNJ) – AstraZeneca to co-promote J&J prostate cancer drug in Japan [Reuters - UK Focus] – AstraZeneca has signed a deal... Market Update on Pfizer Inc. (NYSE:PFE) – Pfizer Announces Top-Line Results Of The First Two Of Five Phase 3 Clinical Trials Of Tofacitinib In Adults With Moderate-To-Severe Chronic Plaque Psoriasis [Business Wire] – Pfizer Inc. announced today top-line results from...
[at Seeking Alpha] – Pfizer ( PFE ) has high hopes for its experimental breast cancer drug palbociclib (PD-0332991), an oral inhibitor of CDK (cyclin-dependent kinases) 4 and 6. The therapy generated excitement among oncologists …
Read more on this.
Pfizer Inc. … [visit site to read more]
Similar posts:- Company Update: Johnson & Johnson (NYSE:JNJ) – AstraZeneca to co-promote J&J prostate cancer drug in Japan [Reuters - UK Focus] – AstraZeneca has signed a deal...
- Market Update on Pfizer Inc. (NYSE:PFE) – Pfizer Announces Top-Line Results Of The First Two Of Five Phase 3 Clinical Trials Of Tofacitinib In Adults With Moderate-To-Severe Chronic Plaque Psoriasis [Business Wire] – Pfizer Inc. announced today top-line results from...
